The Court may soon allow future lawsuits over Ozempic, Wegovy, Mounjaro and other GLP-1s to be brought using a Short Form Complaint, adopting allegations from the MDL Master Complaint.
Novo Nordisk allegedly knew for years about the risk that Ozempic and Rybelsus may cause ileus and other severe gastrointestinal side effects, but failed to warn doctors or patients.
New research has highlighted the risk of gastric illnesses associated with 15 different types of GLP-1 drugs commonly prescribed for Type II diabetes and weight loss management.
